Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 5/20 | 0.41 |
| ▸ | MAOB | P27338 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | IGF1R | P08069 | 2/20 | 0.36 |
| ▸ | SRC | P12931 | 2/20 | 0.36 |
| ▸ | AXL | P30530 | 2/20 | 0.36 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.36 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30430976 | 1.00 | CYP3A4 (0.53) | CYP3A4MAPTUSP2PTGESPTPN1 | |
| Methane SCHEMBL28606274 | 0.98 | CYP3A4 (0.52) | CYP3A4MAPTUSP2PTGESPTPN1 | |
| SCHEMBL17311322 | 0.84 | CYP3A4 (0.52) | CYP3A4MAPTUSP2PTGESPTPN1 | |
| SCHEMBL10470456 | 0.84 | CYP3A4 (0.46) | CYP3A4MAPTUSP2PTGESPTPN1 | |
| SCHEMBL31336001 | 0.84 | CYP3A4 (0.46) | CYP3A4MAPTUSP2PTGESPTPN1 | |
| SCHEMBL10609480 | 0.83 | CYP3A4 (0.52) | CYP3A4MAPTUSP2PTGESPTPN1 | |
| SCHEMBL7896054 | 0.78 | CYP3A4 (0.48) | CYP3A4MAPTUSP2ERN1KDM4E | |
| SCHEMBL31648926 | 0.78 | CYP3A4 (0.48) | CYP3A4MAPTUSP2ERN1KDM4E | |
| SCHEMBL31156341 | 0.75 | MAOB (0.43) | CYP3A4MAPTUSP2PTGESPTPN1 | |
| SCHEMBL31156359 | 0.75 | MAOB (0.43) | CYP3A4MAPTUSP2PTGESPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106340726-B | Magnetic conductive nano metal/carbon aerogels absorbing material and preparation method thereof | 中国工程物理研究院激光聚变研究中心 | 2019-01-25 | — | — | CN | claimed |
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | Neophore Limited (GB) | 2026-02-17 | — | — | US | disclosed |
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2024-12-26 | — | — | US | disclosed |
| EP-4441031-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| EP-4441040-A1 | INDOLINES AS PROTAC COMPOUNDS | Neophore Limited (GB) | 2024-10-09 | — | — | EP | disclosed |
| CN-118317954-A | Indoline as PROTAC compound | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118317949-A | Isoindolines as PMS2 inhibitors | 奈奥芬莱有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | Neophore Limited (GB) | 2023-06-15 | — | — | US | disclosed |
| WO-2023094833-A1 | INDOLINES AS PROTAC COMPOUNDS | Neophore Limited (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094833-A1 | INDOLINES AS PROTAC COMPOUNDS | Neophore Limited (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094834-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2023094834-A1 | ISOINDOLINES AS PMS2 INHIBITORS | Neophore Limited (GB) | 2023-06-01 | — | — | WO | disclosed |
| CN-109293493-B | Novel benzhydryl compounds with mycobacterium tuberculosis inhibiting activity | 清华大学 | 2021-08-03 | — | — | CN | disclosed |
| CN-106340726-B | Magnetic conductive nano metal/carbon aerogels absorbing material and preparation method thereof | 中国工程物理研究院激光聚变研究中心 | 2019-01-25 | — | — | CN | disclosed |
| CN-105601604-B | Dracorhodin and its salt, the preparation method of intermediate and these midbody compounds | 北京颖诺凯胜科技有限公司 | 2018-03-09 | — | — | CN | disclosed |
| WO-2017178498-A1 | CARBONACEOUS MATERIALS, THEIR MANUFACTURING PROCESS AND THEIR USE IN SUPERCAPACITORS | XEROLUTIONS S.L. (ES) | 2017-10-19 | — | — | WO | disclosed |
| CN-106340726-A | Magnetic conductive nano-metal/carbon airgel absorbing material and the preparation method thereof | 中国工程物理研究院激光聚变研究中心 | 2017-01-18 | — | — | CN | disclosed |
| CN-105601604-A | Preparation methods of dracorhodin and salt and intermediates thereof and intermediate compounds | INNOCHEM (BEIJING) TECH CO LTD | 2016-05-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552758-B2 | Inhibitors of MLH1 and/or PMS2 for cancer treatment | MSH2, PMS2, MSH6 | CYP3A4 2245/4885MAPT 4634/4885USP2 1022/4885 |
| US-20230183197-A1 | INHIBITORS OF MLH1 AND/OR PMS2 FOR CANCER TREATMENT | MSH2, PMS2, MSH6 | CYP3A4 3288/4885MAPT 3491/4885USP2 1312/4885 |
| US-20240425453-A1 | ISOINDOLINES AS PMS2 INHIBITORS | PMS2, MSH2, RECQL | CYP3A4 1109/4885MAPT 3789/4885USP2 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.